Paradigm Biocapital Advisors LP
Top Portfolio Positions
35 positions ·
$4,894,261,596 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| ACLX |
Arcellx, Inc.
Healthcare
|
5,774,016 | $662,972,517 | 13.55% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
6,655,703 | $647,267,116 | 13.23% | |
| NUVL |
Nuvalent, Inc.
Healthcare
|
5,324,433 | $545,488,160 | 11.15% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
4,793,020 | $278,522,392 | 5.69% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
7,365,038 | $231,998,697 | 4.74% | |
| GMAB |
Genmab A/S
Healthcare
|
7,967,836 | $213,777,039 | 4.37% | |
| INSM |
INSMED Inc
Healthcare
|
1,254,488 | $205,133,877 | 4.19% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
2,562,154 | $179,735,103 | 3.67% | |
| BLTE |
Belite Bio, Inc
Healthcare
|
1,114,784 | $177,741,160 | 3.63% | |
| ERAS |
Erasca, Inc.
Healthcare
|
10,392,702 | $168,153,918 | 3.44% |
Portfolio Trend
18 quarters · across all stocks
Holdings in URGN
Shares Held
Position Value (USD)
4 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,637,003 | 1,703,949 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $104,772,836 | 4,473,648 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $84,110,875 | 4,216,084 | Shares | Sole | 2025-11-14 | |
| 2025-08-05 | $48,320,407 | 2,332,066 | Shares | Sole | 2025-08-12 | |
| No 13F history on record for this holder in this stock. | ||||||